{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:56:43Z","timestamp":1776387403996,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T00:00:00Z","timestamp":1446508800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Mitsubishi Tanabe"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s12325-015-0255-8","type":"journal-article","created":{"date-parts":[[2015,11,3]],"date-time":"2015-11-03T09:05:39Z","timestamp":1446541539000},"page":"1085-1103","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Effects of Baseline Blood Pressure and Low-Density Lipoprotein Cholesterol on Safety and Efficacy of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus"],"prefix":"10.1007","volume":"32","author":[{"given":"Nobuya","family":"Inagaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maki","family":"Goda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuko","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,11,3]]},"reference":[{"key":"255_CR1","doi-asserted-by":"publisher","first-page":"434","DOI":"10.2337\/diacare.16.2.434","volume":"16","author":"J Stamler","year":"1993","unstructured":"Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434\u201344.","journal-title":"Diabetes Care"},{"key":"255_CR2","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1055\/s-2002-34791","volume":"34","author":"H Sone","year":"2002","unstructured":"Sone H, Katagiri A, Ishibashi S, et al. Effects of lifestyle modifications on patients with type 2 diabetes: the Japan Diabetes Complications Study (JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res. 2002;34:509\u201315.","journal-title":"Horm Metab Res"},{"key":"255_CR3","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.atherosclerosis.2006.04.017","volume":"191","author":"S Oikawa","year":"2007","unstructured":"Oikawa S, Kita T, Mabuchi H, et al. Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). Atherosclerosis. 2007;191:440\u20136.","journal-title":"Atherosclerosis."},{"key":"255_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.2337\/diacare.12.8.573","volume":"12","author":"American Diabetes Association","year":"1989","unstructured":"American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care. 1989;12:573\u20139.","journal-title":"Diabetes Care"},{"key":"255_CR5","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","volume":"358","author":"P Gaede","year":"2008","unstructured":"Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580\u201391.","journal-title":"N Engl J Med"},{"key":"255_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","unstructured":"UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703\u201313.","journal-title":"BMJ"},{"key":"255_CR7","first-page":"S4","volume":"38","author":"American Diabetes Association","year":"2015","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142015: summary of revisions. Diabetes Care. 2015;38:S4.","journal-title":"Diabetes Care"},{"key":"255_CR8","unstructured":"The Japan Diabetes Society. Evidence-based Practice Guideline for the Treatment for Diabetes in Japan. http:\/\/www.jds.or.jp\/modules\/en\/index.php?content_id=44. 2013. Accessed 30 Oct 2015."},{"key":"255_CR9","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/dom.12054","volume":"15","author":"K Stenlof","year":"2013","unstructured":"Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15:372\u201382.","journal-title":"Diabetes Obes Metab"},{"key":"255_CR10","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/S0140-6736(13)60683-2","volume":"382","author":"WT Cefalu","year":"2013","unstructured":"Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52\u00a0week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013;382:941\u201350.","journal-title":"Lancet"},{"key":"255_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2337\/dc13-2762","volume":"38","author":"LA Leiter","year":"2015","unstructured":"Leiter LA, Yoon KH, Arias P, et al. Canagliflozin provides durable glycemic improvements and body weight reduction over 104\u00a0weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015;38:355\u201364.","journal-title":"Diabetes Care"},{"key":"255_CR12","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1007\/s00125-013-3039-1","volume":"56","author":"FJ Lavalle-Gonzalez","year":"2013","unstructured":"Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013;56:2582\u201392.","journal-title":"Diabetologia"},{"key":"255_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/jdi.12266","volume":"6","author":"N Inagaki","year":"2015","unstructured":"Inagaki N, Kondo K, Yoshinari T, Kuki H. Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes: a 52-week open-label study. J Diabetes Investig. 2015;6:210\u20138.","journal-title":"J Diabetes Investig."},{"key":"255_CR14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1517\/14656566.2014.935764","volume":"15","author":"N Inagaki","year":"2014","unstructured":"Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother. 2014;15:1501\u201315.","journal-title":". Expert Opin Pharmacother."},{"key":"255_CR15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1056\/NEJMoa1504720","volume":"15","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;15:1501\u201315. doi:10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"key":"255_CR16","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/S1262-3636(14)72693-X","volume":"40","author":"S Halimi","year":"2014","unstructured":"Halimi S, Verges B. Adverse effects and safety of SGLT-2 inhibitors. Diabetes Metab. 2014;40:S28\u201334.","journal-title":"Diabetes Metab."},{"key":"255_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1177\/1479164114559852","volume":"12","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015;12:90\u2013100.","journal-title":"Diab Vasc Dis Res."},{"key":"255_CR18","unstructured":"Center for Disaese Control and Prevention. National diabetes statics report. 2014. http:\/\/www.cdc.gov\/diabetes\/pubs\/statsreport14\/national-diabetes-report-web.pdf."},{"key":"255_CR19","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s13300-014-0086-7","volume":"5","author":"K Kaku","year":"2014","unstructured":"Kaku K, Maegawa H, Tanizawa Y, et al. Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther. 2014;5:415\u201333.","journal-title":"Diabetes Ther."},{"key":"255_CR20","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/dom.12464","volume":"17","author":"E Araki","year":"2015","unstructured":"Araki E, Tanizawa Y, Tanaka Y, et al. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:665\u201374.","journal-title":"Diabetes Obes Metab"},{"key":"255_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1517\/14656566.2014.887680","volume":"15","author":"Y Tanizawa","year":"2014","unstructured":"Tanizawa Y, Kaku K, Araki E, et al. Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium\u2013glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials. Expert Opin Pharmacother. 2014;15:749\u201366.","journal-title":"Expert Opin Pharmacother"},{"key":"255_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12538","author":"S Ikeda","year":"2015","unstructured":"Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium\u2013glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2015. doi:10.1111\/dom.12538.","journal-title":"Diabetes Obes Metab"},{"key":"255_CR23","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1507\/endocrj.EJ15-0097","volume":"62","author":"Y Seino","year":"2015","unstructured":"Seino Y, Kaku K, Inagaki N, et al. Fifty-two-week long-term clinical study of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Endocr J. 2015;62:593\u2013603.","journal-title":"Endocr J"},{"key":"255_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/jdi.12316","volume":"6","author":"Y Seino","year":"2015","unstructured":"Seino Y, Inagaki N, Haneda M, et al. Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2015;6:443\u201353.","journal-title":"J Diabetes Investig."},{"key":"255_CR25","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1007\/s12325-015-0198-0","volume":"32","author":"T Kadowaki","year":"2015","unstructured":"Kadowaki T, Haneda M, Inagaki N, et al. Efficacy and safety of empagliflozin monotherapy for 52\u00a0weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study. Adv Ther. 2015;32:306\u201318.","journal-title":"Adv Ther."},{"key":"255_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/1574886309666140120100255","volume":"9","author":"N Mikhail","year":"2014","unstructured":"Mikhail N. Safety of canagliflozin in patients with type 2 diabetes. Curr Drug Saf. 2014;9:127\u201332.","journal-title":"Curr Drug Saf."},{"key":"255_CR27","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1111\/jch.12425","volume":"16","author":"MR Weir","year":"2014","unstructured":"Weir MR, Januszewicz A, Gilbert RE, et al. Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus. J Clin Hypertens (Greenwich). 2014;16:875\u201382.","journal-title":"J Clin Hypertens (Greenwich)."},{"issue":"217\u2013223","key":"255_CR28","first-page":"e211","volume":"166","author":"B Neal","year":"2013","unstructured":"Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)\u2014a randomized placebo-controlled trial. Am Heart J. 2013;166:217\u2013223.e211.","journal-title":"Am Heart J"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-015-0255-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0255-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-015-0255-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T11:25:56Z","timestamp":1724412356000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-015-0255-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["255"],"URL":"https:\/\/doi.org\/10.1007\/s12325-015-0255-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"14 September 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2015","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}